Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2009 June;61(2) > Minerva Urologica e Nefrologica 2009 June;61(2):109-13

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA UROLOGICA E NEFROLOGICA

A Journal on Nephrology and Urology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536


eTOC

 

  UROLOGIC ONCOLOGY


Minerva Urologica e Nefrologica 2009 June;61(2):109-13

language: English

Is there an emerging role for neoadjuvant targeted therapy in renal cell carcinoma?

Maruschke M., Hakenberg O. W.

Department of Urology, Rostock University Rostock, Germany


PDF  


The recent developments in the medical treatment of metastatic renal cell carcinoma have raised the question of the neoadjuvant use of targeted therapies in locally advanced renal tumours. Evidence at the level of case reports suggests that down-sizing of large renal carcinomas is feasible and small surgical series have so far shown that later surgical tumour removal is not impaired by neoadjuvant treatment. It is at present, however, far too early to fully assess whether such neoadjuvant treatment has an impact on patient survival or quality of life.

top of page

Publication History

Cite this article as

Corresponding author e-mail